Immuneering Forms an Advisory Board for Pancreatic Cancer
Immuneering Corporation, dedicated to developing innovative cancer therapies, has established a Pancreatic Cancer Advisory Board which demonstrates the company’s commitment to patient care in this challenging field. The formation of this board emphasizes ongoing developments related to IMM-1-104, a promising candidate for treating pancreatic cancer.
The Role of the Advisory Board
This newly formed advisory board includes prestigious experts in oncology who will provide critical insights and guidance to enhance Immuneering's strategic direction. Their deep understanding of clinical research will support the company as it advances its clinical programs, particularly the lead candidate IMM-1-104.
Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering, expressed enthusiasm about the board's assembly. He stated, "We are thrilled to welcome such an accomplished group of oncologists whose insights into the clinical landscape will be invaluable as we push forward with IMM-1-104’s development toward helping pancreatic cancer patients effectively."
The Members of the Advisory Board
The Pancreatic Cancer Advisory Board is comprised of renowned professionals in the field:
- Tanios Bekaii-Saab, M.D., from the Mayo Clinic, known for his extensive research in pancreatic oncology.
- Vincent Chung, M.D., FACP, a professor at City of Hope, focuses on medical oncology and therapeutic research.
- Shubham Pant, M.D., a GI Medical Oncology professor at MD Anderson Cancer Center, recognized for contributions to advancing treatment outcomes.
- Jordan Berlin, M.D., FASCO, from Vanderbilt-Ingram Cancer Center, specializes in hematology and oncology with leadership experience.
Expertise Supporting Clinical Development
The collective expertise of these esteemed physicians will guide Immuneering as it seeks new pathways for improving patient outcomes in pancreatic cancer. With a focus on IMM-1-104, the board will also lend a hand in the strategic planning and execution of clinical trials, ensuring that Immuneering maximizes the potential of its offerings.
About IMM-1-104
IMM-1-104 represents a novel approach in the oncology arena, aimed at targeting RAS-related pathways which are critical in many types of cancer, including pancreatic. By utilizing Deep Cyclic Inhibition, the goal is to selectively affect cancer cells more than healthy ones, thereby reducing damage to the patient's normal tissues while enhancing therapeutic efficacy.
This promising treatment is currently undergoing evaluation in a Phase 1/2a study, targeting patients harboring RAS mutations, which is instrumental for the advancement of personalized medicine in oncology.
About Immuneering Corporation
As a clinical-stage oncology firm, Immuneering aims to innovate with its RAS/RAF targeted therapies. The company's flagship candidate, IMM-1-104, is an oral medication that operates on a once-daily dosing schedule, emphasizing convenience for patients undergoing treatment. In addition to IMM-1-104, Immuneering is also advancing IMM-6-415, which targets both RAS and RAF mutations, across its pipeline to broaden treatment accessibility.
Looking Ahead
With a firm commitment to addressing significant unmet needs in pancreatic cancer, Immuneering continues to engage with its expert community, including the newly formed advisory board, to help navigate its clinical pathways and find effective solutions for patients.
Frequently Asked Questions
What is the purpose of the Pancreatic Cancer Advisory Board?
The board aims to provide strategic guidance to Immuneering as it advances its clinical programs, particularly focusing on IMM-1-104.
Who are the members of the advisory board?
The board includes esteemed oncologists such as Tanios Bekaii-Saab, Vincent Chung, Shubham Pant, and Jordan Berlin.
What is the significance of IMM-1-104?
IMM-1-104 is designed to selectively target cancer cells, particularly those with RAS mutations, offering a potential new therapy for pancreatic cancer patients.
How does Immuneering plan to utilize the board's expertise?
The expertise will guide the strategic development of clinical trials and optimize treatment approaches for cancer patients.
What other candidates are in Immuneering's pipeline?
In addition to IMM-1-104, Immuneering is developing IMM-6-415, which targets RAS and RAF mutations.
